Mater Research
Support Us
Home   Clinical Trials
Back

ACUMEN - Enhancing treatment outcomes after after gynaecological cancer through exercise

Gynaecological cancer

Exercise reduces the detrimental side effects of cancer treatments. However, most women recovering from gynaecological cancer have limited access to the support that would help them safely integrate exercise into their daily lives.

The ACUMEN exercise study addresses this critical yet unmet need. The ACUMEN study aims to improve women’s overall wellbeing and important aspects of health after treatment for gynaecological cancer, and to demonstrate the benefits of exercise as cost-effective ‘usual care’ after treatment.

In this study, eligible women will receive 12 weeks of individualised exercise training coached by an exercise physiologist. While the study is based in Brisbane and expert in-person in gyms is available in Brisbane, there is a significant appetite amongst affected women treated at Mater throughout Queensland who also would appreciate exercise support. The ACUMEN team can also deliver exercise supervision via innovative telehealth delivery to women outside of Brisbane. All exercise coaching is delivered one-on-one, there is no group work.

Category
Trial Status
Not yet recruiting
Trial Phase
Phase 0
Registry Listing
Trial contact details
Contact Person
Dr Vivian Chiu
Email
What you need to know

Who can take part?

  • Any woman over the age of 18 years who has been treated with surgery, chemotherapy or radiotherapy for a cancer of the uterus, ovaries, fallopian tubes, cervix, vulva or vagina in the last 5 years.
  •  Must be more than one month since surgery
  • Not on acute treatment (intravenous chemotherapy or radiotherapy) while enrolled
  • If wishing to participate via telehealth, must have a mobile phone or computer

What is involved for you?

  • Enrolment is for 24 weeks.
  • Completion of a health survey on Weeks 1, 12 and 24.
  • Commence exercise program in Week 1, which is undertaken until the end of Week 12.
  • You will be supervised in a mix of aerobic, resistance and flexibility training for the 12 weeks, tailored to you needs and capabilities.
  • In the first six weeks you will be coached by an exercise physiologist for two sessions per week, and trained to undertake one by yourself once per week.
  • In the second six weeks, you will be coached for one session per week, and encouraged to undertake two sessions by yourself. This is to build your ability to safely undertake exercise by yourself by the end of the program.

Trial dates

This trial is accepting participants until July 2023.

Back

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.

23

May

Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >| 

TrIAl Categories

IN THIS SECTION

Skip Navigation Links.